The drug is now indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors that lack suitable alternative treatments or that have progressed on treatment.
Following a review of data from 15 different cancer types, the FDA has granted accelerated approval to the programmed death 1 (PD-1) inhibitor pembrolizumab for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that lack suitable alternative treatments or that have progressed on treatment. The indication also includes patients with colorectal cancer (CRC) that is MSI-H or dMMR and who have progressed on fluoropyrimidine, oxaliplatin, and irinotecan.
The data from 5 uncontrolled, multi-center, single-arm studies, included 149 patients with MSI-H or dMMR cancers—a majority (90) had CRC and the remaining 59 were diagnosed with one of 14 other cancers. Patients were treated with 200 mg pembrolizumab every 3 weeks, or 10 mg/kg every 2 weeks, for a maximum of 24 weeks, until unacceptable toxicity or progression was observed.
The objective response rate was 39.6% (95% CI, 31.7 to 47.9) and the minimum duration of response was 6 months in 78% of patients who responded to the PD-1 inhibitor. Further, 11 complete responses and 48 partial responses were documented.
Merck, which has developed the drug, is expected to conduct further studies to confirm the clinical benefit of pembrolizumab for this indication.
In the past month, pembrolizumab has received FDA approvals for several indications, including advanced or metastatic urothelial carcinoma and metastatic nonsquamous non-small cell lung cancer (NSCLC). It was one of the first immuno-oncology agents to be approved for melanoma and for non-small cell lung cancer.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More